+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 50Years - 120Years
All Genders
ID04663750

Comparing Surgery Plus Anti-VEGF Injections to Anti-VEGF Alone for Submacular Haemorrhage in Wet Age-Related Macular Degeneration

Led by King's College Hospital NHS Trust · Updated on 2026-09-11

210

Participants Needed

42

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

The trial investigates treatments for submacular haemorrhage SMH, a serious complication of wet age-related macular degeneration AMD that can cause severe vision loss. Researchers aim to compare the current standard treatment of anti-VEGF injections with a combination of anti-VEGF injections plus eye surgery to see if surgery improves vision outcomes. This is a phase 3 randomized controlled trial involving adults aged 50 and older with SMH due to wet AMD. Participants are randomly assigned to one of two groups one group receives standard anti-VEGF injections starting at baseline and continuing monthly for three doses, then every two months until 12 months. The other group receives the same anti-VEGF injection schedule combined with vitrectomy surgery, which involves removing the eyes vitreous gel, injecting a clot-busting drug TPA, and filling the eye with gas to help clear the blood clot. Surgery patients also follow specific head positioning after the procedure and have follow-up visits the day after and one week after surgery. Throughout the 12-month study, participants attend regular visits for injections and vision assessments, including tests of visual acuity and questionnaires about visual function and quality of life. Researchers measure vision improvement using Early Treatment of Diabetic Retinopathy Study ETDRS letter scores and other vision-related tests. Safety and vision are monitored with clinical exams at 6 and 12 months, and adherence to treatment schedules is tracked to evaluate the effectiveness of the treatments.

CONDITIONS

Brief Title

Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).

Research Team

R

Riti Desai, M.Sc.,M.Phil.

L

Lisa Ramazzotto, M.Pharm

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here